Dermatologic Manifestations of Viral Hemorrhagic Fevers Treatment & Management
- Author: Amira M Elbendary, MBBCh, MSc; Chief Editor: William D James, MD more...
Rapidly transfer the patient to a hospital with minimal trauma in order to prevent trauma to the fragile capillary bed.
The judicious use of sedative, pain-relieving, and amnesic medications can be helpful in managing malaise, confusion, myalgia, and hyperesthesia. Intramuscular injections and the use of aspirin and other anticoagulant drugs should be avoided.
Adequate hydration reduces the death rate, and oral rehydration may not be adequate.
Intensive supportive care is necessary for most cases of viral hemorrhagic fever. General supportive care principles apply to the treatment of hemodynamic, hematologic, pulmonary, and neurologic manifestations of viral hemorrhagic fever. Supportive care entails maintaining the patient's oxygen status and blood pressure and balancing fluid and electrolyte levels. Blood, platelet, and plasma replacement and management can be crucial, depending on the case. Convalescent plasma infusions may be effective in Argentinian hemorrhagic fever, if they are administered within the first 8 days of onset.
In Dengue fever, for which the main pathology is capillary leakage, brisk infusion with crystalloids should be instituted, followed by colloids or albumin if there is no response.
In Hantavirus infection, acute renal failure recovery may be accompanied by severe polyuria that should be managed carefully with close observation of fluid balance and electrolytes values.
Antiviral therapy with ribavirin may be useful in several viral hemorrhagic fevers, especially those caused by Arenaviruses. Although ribavirin inhibits viral DNA and RNA synthesis, it is not sensitive to the replication mechanisms of all RNA viruses. Ribavirin is proven effective in the treatment of Lassa fever and Congo-Crimean hemorrhagic fever. It is somewhat effective in the treatment of other arenavirus and Hantavirus infections, in which it decreases mortality rates when used early in the course of the disease. Additionally, discovery of compounds with antiflaviviral activity have shown promise. Currently, several ribavirin analogues are undergoing clinical trials.
Interferon-alfa has shown promising results in Arenaviral infections in vitro as an adjunctive therapy with ribavirin.
Vaccination may be considered. The only approved vaccine is for yellow fever. The WHO Strategic Advisory Group recommends a single primary dose for most travelers; a booster dose of the vaccine is no longer required, as the vaccine was found to confer sustained immunity and lifelong protection against yellow fever disease.
Nonapproved vaccines include that developed for Argentinian viral hemorrhagic fever. This vaccine is a live-attenuated, investigational vaccine. It also seems to offer protection against Bolivian viral hemorrhagic fever. Both inactivated and live-attenuated vaccines for RVF are under investigation. No vaccines are currently available for filovirus infection or dengue. Preliminary results suggest potential for successful prevaccination and postvaccination exposure against Ebola and Marburg viruses.[37, 52, 53]
Persons percutaneously or mucocutaneously exposed to blood, excretions, or secretions of individuals who are infected should wash the affected areas with soap and water. Affected mucous membranes should be irrigated with water or sodium chloride solution.
Additional information is available from the Centers for Disease Control and Prevention. See Infection Control for Viral Haemorrhagic Fevers in the African Health Care Setting and Questions and Answers on Ebola.
Consultation with the following specialists may be warranted:
Infectious disease specialist
Internal medicine specialist
Other specialists as necessary
Fluid and electrolyte balance should be maintained.
Malaise and myalgia, among other symptoms, dictate bed rest restrictions.
Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol. 2008 Jan. 89 (Pt 1):1-47. [Medline].
Kumar A. Ebola virus altered innate and adaptive immune response signalling pathways: Implications for novel therapeutic approaches. Infect Disord Drug Targets. 2016 Jan 7. [Medline].
Papa A, Tsergouli K, Çağlayık DY, Bino S, Como N, Uyar Y, et al. Cytokines as biomarkers of Crimean-Congo hemorrhagic fever. J Med Virol. 2016 Jan. 88 (1):21-7. [Medline].
Simmons CP, Farrar JJ, Nguyen vV, Wills B. Dengue. N Engl J Med. 2012 Apr 12. 366(15):1423-32. [Medline].
Vejbaesya S, Thongpradit R, Kalayanarooj S, Luangtrakool K, Luangtrakool P, Gibbons RV, et al. HLA Class I Supertype Associations With Clinical Outcome of Secondary Dengue Virus Infections in Ethnic Thais. J Infect Dis. 2015 Mar 4. [Medline].
Chen CY, Lee MY, Lin KD, Hsu WH, Lee YJ, Hsiao PJ, et al. Diabetes mellitus increases severity of thrombocytopenia in dengue-infected patients. Int J Mol Sci. 2015 Feb 10. 16(2):3820-30. [Medline]. [Full Text].
Patra G, Ghosh M, Modak D, Bandopadhyay B, Saha B, Mukhopadhyay S. Status of circulating immune complexes, IL8 titers and cryoglobulins in patients with dengue infection. Indian J Exp Biol. 2015 Nov. 53 (11):719-25. [Medline].
Bachal R, Alagarasu K, Singh A, Salunke A, Shah P, Cecilia D. Higher levels of dengue-virus-specific IgG and IgA during pre-defervescence associated with primary dengue hemorrhagic fever. Arch Virol. 2015 Oct. 160 (10):2435-43. [Medline].
Jansen van Vuren P, Shalekoff S, Grobbelaar AA, Archer BN, Thomas J, Tiemessen CT, et al. Serum levels of inflammatory cytokines in Rift Valley fever patients are indicative of severe disease. Virol J. 2015 Oct 6. 12:159. [Medline].
Connolly-Andersen AM, Thunberg T, Ahlm C. Endothelial activation and repair during hantavirus infection: association with disease outcome. Open Forum Infect Dis. 2014 Mar. 1(1):ofu027. [Medline]. [Full Text].
Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 2008 Apr. 78(1):162-9. [Medline].
Centers for Disease Control and Prevention. Review of Human-to-Human Transmission of Ebola Virus. Available at http://www.cdc.gov/vhf/ebola/transmission/human-transmission.html. Accessed: October 17, 2014.
Fhogartaigh CN, Aarons E. Viral haemorrhagic fever. Clin Med. 2015 Feb. 15(1):61-6. [Medline].
Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014 Oct 9. 371 (15):1418-25. [Medline].
Dixon MG, Schafer IJ, Centers for Disease Control and Prevention (CDC). Ebola viral disease outbreak--West Africa, 2014. MMWR Morb Mortal Wkly Rep. 2014 Jun 27. 63 (25):548-51. [Medline].
WHO Ebola Response Team. Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med. 2014 Oct 16. 371 (16):1481-95. [Medline].
Hsieh YH. Temporal Course of 2014 Ebola Virus Disease (EVD) Outbreak in West Africa Elucidated through Morbidity and Mortality Data: A Tale of Three Countries. PLoS One. 2015. 10 (11):e0140810. [Medline].
Fallah MP, Skrip LA, Gertler S, Yamin D, Galvani AP. Quantifying Poverty as a Driver of Ebola Transmission. PLoS Negl Trop Dis. 2015 Dec. 9 (12):e0004260. [Medline].
van Panhuis WG, Choisy M, Xiong X, et al. Region-wide synchrony and traveling waves of dengue across eight countries in Southeast Asia. Proc Natl Acad Sci U S A. 2015 Oct 20. 112 (42):13069-74. [Medline].
Tiawilai T, Tiawilai A, Nunthanid S. Dengue Infection in Elderly Patients. Southeast Asian J Trop Med Public Health. 2015. 46 Suppl 1:165-8. [Medline].
Southern PJ. Arenaviridae: the viruses and their replication. Fields BN, Knipe DN, Howley PM, et al, eds. Fields Virology. 3rd ed. Philadelphia, Pa: Lippincott-Raven; 1996. 1505-19.
Peters CJ, Linthicum KJ. Rift valley fever. Handbook of Zoonoses. Boca Raton, Fla: CRC Press; 1994. 129-43.
Kahlon SS, Peters CJ, Leduc J, Muchiri EM, Muiruri S, Njenga MK. Severe Rift Valley fever may present with a characteristic clinical syndrome. Am J Trop Med Hyg. 2010 Mar. 82(3):371-5. [Medline].
Seo JH, Park KH, Lim JY, Youn HS. Hemorrhagic fever with renal syndrome (HFRS, Korean hemorrhagic fever). Pediatr Nephrol. 2007 Jan. 22(1):156-7. [Medline].
Chowell G, Nishiura H. Transmission dynamics and control of Ebola virus disease (EVD): a review. BMC Med. 2014 Oct 10. 12(1):196. [Medline].
Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014 Sep 12. 345(6202):1369-72. [Medline].
Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014 Nov 27. 371(22):2092-100. [Medline]. [Full Text].
Lado M, Walker NF, Baker P, Haroon S, Brown CS, Youkee D, et al. Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study. Lancet Infect Dis. 2015 Sep. 15 (9):1024-33. [Medline].
Feldmann H. Marburg hemorrhagic fever--the forgotten cousin strikes. N Engl J Med. 2006 Aug 31. 355(9):866-9. [Medline].
Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis. 2006 Oct. 19(5):429-36. [Medline].
No Authors Listed. Dengue haemorrhagic fever: early recognition, diagnosis and hospital management--an audiovisual guide for health-care workers responding to outbreaks. Wkly Epidemiol Rec. 2006 Sep 22. 81(38):362-3. [Medline].
Munir MA, Alam SE, Khan ZU, Saeed Q, Arif A, Iqbal R, et al. Dengue fever in patients admitted in tertiary care hospitals in Pakistan. J Pak Med Assoc. 2014 May. 64(5):553-9. [Medline].
Kirawittaya T, Yoon IK, Wichit S, Green S, Ennis FA, Gibbons RV, et al. Evaluation of Cardiac Involvement in Children with Dengue by Serial Echocardiographic Studies. PLoS Negl Trop Dis. 2015 Jul. 9 (7):e0003943. [Medline].
Mallhi TH, Khan AH, Adnan AS, Sarriff A, Khan YH, Jummaat F. Clinico-laboratory spectrum of dengue viral infection and risk factors associated with dengue hemorrhagic fever: a retrospective study. BMC Infect Dis. 2015 Sep 30. 15:399. [Medline].
Bausch DG, Sprecher AG, Jeffs B, Boumandouki P. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res. 2008 Apr. 78(1):150-61. [Medline].
Farhadpour F, Telmadarraiy Z, Chinikar S, Fakoorziba MR, Akbarzadeh K, Moemenbellah-Fard MD, et al. Molecular Detection of Crimean-Congo Hemorrhagic Fever Virus in Ticks Collected From Infested Livestock Populations in a New Endemic Area, South of Iran. Trop Med Int Health. 2016 Jan 13. [Medline].
Christie A, Davies-Wayne GJ, Cordier-Lassalle T, et al. Possible sexual transmission of Ebola virus - Liberia, 2015. MMWR Morb Mortal Wkly Rep. 2015 May 8. 64 (17):479-81. [Medline].
Fink S. Ebola Researchers Take New Look at Risk of Sexual Transmission. NYTimes.com. Available at http://www.nytimes.com/2015/04/17/world/africa/ebola-researchers-take-new-look-at-risk-of-sexual-transmission.html. April 16, 2015; Accessed: February 3, 2015.
Deen GF, Knust B, Broutet N, et al. Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Preliminary Report. N Engl J Med. 2015 Oct 14. [Medline].
Formenty P, Leroy EM, Epelboin A, Libama F, Lenzi M, Sudeck H, et al. Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis. 2006 Jun 1. 42 (11):1521-6. [Medline].
Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis. 1999 Feb. 179 Suppl 1:S87-91. [Medline].
Noisakran S, Perng GC. Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus infection. Exp Biol Med (Maywood). 2008 Apr. 233(4):401-8. [Medline].
Kurosaki Y, Grolla A, Fukuma A, Feldmann H, Yasuda J. Development and evaluation of a simple assay for Marburg virus detection using a reverse transcription-loop-mediated isothermal amplification method. J Clin Microbiol. 2010 Jul. 48(7):2330-6. [Medline].
Leroy EM, Baize S, Lu CY, McCormick JB, Georges AJ, Georges-Courbot MC, et al. Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting. J Med Virol. 2000 Apr. 60 (4):463-7. [Medline].
Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res. 2008 Apr. 78(1):125-31. [Medline].
Ghosh D, Basu A. Present perspectives on flaviviral chemotherapy. Drug Discov Today. 2008 Jul. 13(13-14):619-24. [Medline].
Morrill JC, Jennings GB, Cosgriff TM, Gibbs PH, Peters CJ. Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. Rev Infect Dis. 1989 May-Jun. 11 Suppl 4:S815-25. [Medline].
Staples JE, Bocchini JA Jr, Rubin L, Fischer M, Centers for Disease Control and Prevention (CDC). Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015 Jun 19. 64 (23):647-50. [Medline].
Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, Grolla A, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol. 2006 Oct. 80(19):9659-66. [Medline].
Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006 Nov. 13(11):1267-77. [Medline].
Kothari VM, Karnad DR, Bichile LS. Tropical infections in the ICU. J Assoc Physicians India. 2006 Apr. 54:291-8. [Medline].
Mattia JG, Vandy MJ, Chang JC, et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis. 2015 Dec 22. [Medline].
Howlett P, Brown C, Helderman T, Brooks T, Lisk D, Deen G, et al. Ebola Virus Disease Complicated by Late-Onset Encephalitis and Polyarthritis, Sierra Leone. Emerg Infect Dis. 2016 Jan. 22 (1):150-2. [Medline].
Epstein L, Wong KK, Kallen AJ, Uyeki TM. Post-Ebola Signs and Symptoms in U.S. Survivors. N Engl J Med. 2015 Dec 17. 373 (25):2484-6. [Medline].
Siriyakorn N, Insiripong S. Fatal Rhabdomyolysis in Dengue Hemorrhagic Fever: A Case Report. Southeast Asian J Trop Med Public Health. 2015. 46 Suppl 1:149-52. [Medline].
Vachvanichsanong P, McNeil E. Electrolyte Disturbance and Kidney Dysfunction in Dengue Viral Infection. Southeast Asian J Trop Med Public Health. 2015. 46 Suppl 1:108-17. [Medline].
Ramírez-Fonseca T, Segarra-Torres A, Jaume-Anselmi F, Ramírez-Rivera J. Dengue Fever: A Rare Cause Of Immune Thrombocytopenia. Bol Asoc Med P R. 2015 Apr-Jun. 107 (2):51-3. [Medline].
Gülhan B, Kanık-Yüksek S, Çetin İİ, Özkaya-Parlakay A, Tezer H. Myocarditis in a Child with Crimean-Congo Hemorrhagic Fever. Vector Borne Zoonotic Dis. 2015 Sep. 15 (9):565-7. [Medline].
Fasina FO, Adenubi OT, Ogundare ST, Shittu A, Bwala DG, Fasina MM. Descriptive analyses and risk of death due to Ebola Virus Disease, West Africa, 2014. J Infect Dev Ctries. 2015 Dec 30. 9 (12):1298-307. [Medline].
Zhang X, Rong Y, Sun L, Liu L, Su H, Zhang J, et al. Prognostic Analysis of Patients with Ebola Virus Disease. PLoS Negl Trop Dis. 2015 Sep. 9 (9):e0004113. [Medline].
|Virus Family and Genus||Type of Hemorrhagic Fever||Reservoir Host||Geographic Distribution|
Lassa (West Africa)
Brazilian or Sao Paulo
Mosquito and contact with infected blood in slaughter houses
Contact with infected rodents and their excreta
|Crimea, Central Africa, South Africa, Iraq, Pakistan, Turkey, Iran, Afghanistan, Russia
Korea, Eastern Europe, Russia, Scandinavia
North, Central, and South America
Tropical Africa, South America
Entire tropical zone
India, Southeast Asia
Infected monkeys were implicated but no known definite reservoir
|Virus Family and Type of VHF||Mortality Rate, %|
Argentinian and Bolivian
Lassa (West African)
Venezuelan and Sao Paulo
Korean and Seoul